Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular PsoriasisVanda expects to immediately begin preparing ...
D.C. biotech Vanda Pharmaceuticals acquires AnaptysBio’s drug for rare skin disorder
D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...
AnaptysBio, Vanda announce exclusive global license agreement for Vanda
Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...
Yahoo Finance6d
US retail investors dive into tech stocks in response to DeepSeek selloff
according to data released by Vanda Research on Wednesday. Retail investors poured one out of every three dollars of their investments into Nvidia shares in the first days of this week when the AI ...
Yahoo Finance6d
US retail investors dive into tech stocks in response to DeepSeek selloff
(Reuters) - Individual investors responded to the market selloff earlier this week triggered by concerns regarding a Chinese artificial intelligence startup by buying a wide array of technology stocks ...
Vanda stock holds Buy rating, $18 target from H.C. Wainwright
H.C. Wainwright maintained a Buy rating on Vanda Pharmaceuticals (NASDAQ:VNDA) with a price target of $18.00, representing significant upside potential from the current price of $4.31. According to ...